 Connection
Anthony Elias to Neoplasm Metastasis
This is a "connection" page, showing publications Anthony Elias has written about Neoplasm Metastasis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.571 |
|
|
|
-
Elias AD, Sams S. Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR. Oncology (Williston Park). 2013 Jun; 27(6):526-7, 566.
Score: 0.093
-
Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res. 2004; 6(2):93-101.
Score: 0.049
-
Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003 Feb; 77(3):245-52.
Score: 0.046
-
Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant. 2002; 8(4):198-205.
Score: 0.042
-
Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 12; 9(23):8801-8808.
Score: 0.039
-
Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 07 01; 112(7):698-707.
Score: 0.038
-
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478.
Score: 0.037
-
Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018 Aug; 171(1):11-20.
Score: 0.033
-
Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Sch?ffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905.
Score: 0.029
-
Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995 Aug; 13(8):2043-9.
Score: 0.027
-
Elias AD. Salvage therapy for soft tissue sarcomas. Semin Oncol. 1994 Aug; 21(4 Suppl 7):76-81.
Score: 0.025
-
Curigliano G, Pivot X, Cort?s J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013 Oct; 22(5):650-6.
Score: 0.024
-
Sch?ffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013 Oct; 49(15):3219-28.
Score: 0.023
-
Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 1992 Jun 01; 79(11):3036-44.
Score: 0.022
-
Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95.
Score: 0.009
-
Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E, Antman K. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996 Nov; 14(11):2984-92.
Score: 0.007
-
Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer. 1996 Jun 01; 77(11):2393-9.
Score: 0.007
-
Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol. 1994 Jan; 12(1):37-44.
Score: 0.006
-
Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr. 1994; (16):91-4.
Score: 0.006
-
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep. 1987 Feb; 71(2):119-25.
Score: 0.004
-
Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov; 4(11):1592-7.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|